Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer

被引：18

作者：

Yamada, Yasuhide ^{[1
,21
,22
]}

Koizumi, Wasaburo ^{[2
]}

Nishikawa, Kazuhiro ^{[3
]}

Gotoh, Masahiro ^{[4
]}

Fuse, Nozomu ^{[5
]}

Sugimoto, Naotoshi ^{[6
]}

Nishina, Tomohiro ^{[7
]}

Amagai, Kenji ^{[8
]}

Chin, Keisho ^{[9
]}

Niwa, Yasumasa ^{[10
]}

Tsuji, Akihito ^{[11
]}

Imamura, Hiroshi ^{[12
]}

Tsuda, Masahiro ^{[13
]}

Yasui, Hirofumi ^{[14
]}

Fujii, Hirofumi ^{[15
]}

Yamaguchi, Kensei ^{[16
]}

Yasui, Hisateru ^{[17
]}

Hironaka, Shuichi ^{[18
]}

Shimada, Ken ^{[19
]}

Hyodo, Ichinosuke ^{[20
]}

机构：

[1] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan

[2] Kitasato Univ Hosp, Dept Gastroenterol, Sagamihara, Kanagawa, Japan

[3] Osaka Gen Med Ctr, Dept Surg, Osaka, Japan

[4] Osaka Med Coll Hosp, Canc Chemotherapy Ctr, Takatsuki, Osaka, Japan

[5] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[6] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Clin Oncol, Osaka, Japan

[7] Natl Hosp Org, Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Ehime, Japan

[8] Ibaraki Cent Hosp, Dept Gastroenterol, Kasama, Ibaraki, Japan

[9] Canc Inst Hosp JFCR, Dept Gastroenterol, Tokyo, Japan

[10] Aichi Canc Ctr Hosp, Dept Endoscopy, Nagoya, Aichi, Japan

[11] Kagawa Univ, Dept Clin Oncol, Takamatsu, Kagawa, Japan

[12] Sakai City Hosp, Dept Surg, Sakai, Osaka, Japan

[13] Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan

[14] Shizuoka Canc Ctr, Diyis Gastrointestinal Oncol, Shizuoka, Japan

[15] Jichi Med Univ, Dept Clin Oncol, Shimotsuke, Tochigi, Japan

[16] Saitama Canc Ctr, Div Gastroenterol, Saitama, Japan

[17] Natl Hosp Org, Dept Med Oncol, Kyoto Med Ctr, Kyoto, Japan

[18] Chiba Canc Ctr, Clin Trial Promot Dept, Chiba, Japan

[19] Showa Univ, Dept Internal Med, Northern Yokohama Hosp, Tokyo, Japan

[20] Univ Tsukuba, Div Gastroenterol, Tsukuba, Ibaraki, Japan

[21] Natl Ctr Global Hlth & Med, Comprehens Canc Ctr, Shinjuku Ku, Tokyo, Japan

[22] Hamamatsu Univ, Dept Med Oncol, Sch Med, Hamamatsu, Shizuoka, Japan

来源：

CANCER SCIENCE | 2019年 / 110卷 / 09期

关键词：

fluorouracil; gastric cancer; oxaliplatin; S-1; sex; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; TOXICITY; 5-FLUOROURACIL; CHEMOTHERAPY; JAPANESE; THERAPY; CYP2A6; PLASMA; TRIAL;

D O I：

10.1111/cas.14117

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Previous studies have shown sex-related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown. We examined sex-related differences in the safety of S-1 plus oxaliplatin (SOX) and S-1 plus cisplatin (CS) in 663 metastatic gastric cancer patients taking part in a phase III study. The incidences of leukopenia (odds ratio [OR] 1.9; P = .015), neutropenia (OR 2.2; P = .002), nausea (OR 2.0; P = .009), and vomiting (OR 2.8; P < .001) were increased in women versus men treated with SOX, while vomiting (OR 2.9; P < .001) and stomatitis (OR 1.8; P = .043) were increased in women versus men treated with CS. In contrast, male patients treated with CS experienced thrombocytopenia more often (OR 0.51; P = .009). The mean relative dose intensity of S-1 in SOX was 75.4% in women and 81.4% in men (P = .032). No difference in efficacy was observed between women and men undergoing either regimen. Sex-related differences in adverse reactions during SOX and CS treatment were confirmed in this phase III study. Further translational research studies are warranted to pursue the cause of this difference.

引用

页码：2875 / 2883

页数：9

共 25 条

[1] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update [J].

Amstutz, Ursula ;

Henricks, Linda M. ;

Offer, Steven M. ;

Barbarino, Julia ;

Schellens, Jan H. M. ;

Swen, Jesse J. ;

Klein, Teri E. ;

McLeod, Howard L. ;

Caudle, Kelly E. ;

Diasio, Robert B. ;

Schwab, Matthias .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) :210-216

[2] Accounting for sex in the genome [J].

不详 .

NATURE MEDICINE, 2017, 23 (11) :1243-1243

[3] Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma [J].

Chansky, K ;

Benedetti, J ;

Macdonald, JS .

CANCER, 2005, 103 (06) :1165-1171

[4] POPULATION STUDY OF DIHYDROPYRIMIDINE DEHYDROGENASE IN CANCER-PATIENTS [J].

ETIENNE, MC ;

LAGRANGE, JL ;

DASSONVILLE, O ;

FLEMING, R ;

THYSS, A ;

RENEE, N ;

SCHNEIDER, M ;

DEMARD, F ;

MILANO, G .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2248-2253

[5] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Dikshit, Rajesh ;

Eser, Sultan ;

Mathers, Colin ;

Rebelo, Marise ;

Parkin, Donald Maxwell ;

Forman, David ;

Bray, Freddie .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386

[6] Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity [J].

Froehlich, Tanja K. ;

Amstutz, Ursula ;

Aebi, Stefan ;

Joerger, Markus ;

Largiader, Carlo R. .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (03) :730-739

[7] CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1 [J].

Fujita, Ken-ichi ;

Yamamoto, Wataru ;

Endo, Shoji ;

Endo, Hisashi ;

Nagashima, Fumio ;

Ichikawa, Wataru ;

Tanaka, Ryuhei ;

Miya, Toshimichi ;

Araki, Kazuhiro ;

Kodama, Keiji ;

Sunakawa, Yu ;

Narabayashi, Masaru ;

Miwa, Keisuke ;

Ando, Yuichi ;

Akiyama, Yuko ;

Kawara, Kaori ;

Kamataki, Tetsuya ;

Sasaki, Yasutsuna .

CANCER SCIENCE, 2008, 99 (05) :1049-1054

[8]

HEGGIE GD, 1987, CANCER RES, V47, P2203

[9] Human CYP2A6 is induced by estrogen via estrogen receptor [J].

Higashi, Eriko ;

Fukami, Tatsuki ;

Itoh, Masahiro ;

Kyo, Satoru ;

Inoue, Masaki ;

Yokoi, Tsuyoshi ;

Nakajima, Miki .

DRUG METABOLISM AND DISPOSITION, 2007, 35 (10) :1935-1941

[10] Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function [J].

Ikeda, M ;

Furukawa, H ;

Imamura, H ;

Shimizu, J ;

Ishida, H ;

Masutani, S ;

Tatsuta, M ;

Kawasaki, T ;

Satomi, T .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (01) :25-32

← 1 2 3 →